Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab and Trastuzumab in HER2+ Esophagogastric Cancer with Persistent ctDNA
NCT04510285Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, trastuzumab in esophageal cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2020; status: terminated.
02
Drugs
03
Conditions
esophageal cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04510285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510285.